Scientific deep-dive
Two Studies, One Comparison, Two Answers
One real-world study found no cardiovascular difference between the two drugs. Another found semaglutide 29% better. Working out why they disagree is more useful than either answer.
Two real-world studies published in 2026 compared semaglutide against tirzepatide on cardiovascular outcomes. One found no meaningful difference. The other found semaglutide reduced major cardiovascular events by 29%.[1][2] Both used large databases and careful matching. Working out why they disagree is more useful than either answer.
The two results
| Study | Population | Result |
|---|---|---|
| Trial-emulation study | Type 2 diabetes | Tirzepatide vs semaglutide, HR 1.06 (95% CI 0.95–1.18) — comparable |
| Claims-database study | Overweight or obesity with cardiovascular disease, without diabetes | Semaglutide vs tirzepatide, HR 0.71 (p=0.046) and 0.78 (p=0.040) |
Reason one: they studied different people
This is the most straightforward explanation and possibly sufficient on its own. One study looked at people with type 2 diabetes. The other looked at people with overweight or obesity and established atherosclerotic cardiovascular disease but no diabetes.
Those groups have different baseline risks, different reasons for being prescribed either drug, and different competing causes of cardiovascular events. There is no rule that two drugs must rank identically in both.
Reason two: one result is marginal
The p-values in the claims study are 0.046 and 0.040. Those clear the conventional threshold by a hair. A finding at p=0.046 is one that would frequently not replicate, and it should be read as “possibly something” rather than as a demonstration.
Reason three, and the one to learn from
The claims study also ran a per-protocol analysis, censoring patients when they had a gap in therapy of more than 30 days. In that analysis the hazard ratio moved from 0.71 to 0.43, and from 0.78 to 0.57. The paper reports that far more dramatic effect as support for its main result.
An effect that grows sharply once you exclude the people who stopped is a warning sign, not a confirmation.
Excluding people who discontinue removes a specific kind of patient: the ones who could not tolerate the drug, could not afford it, got sicker, or were hospitalized. The people who leave systematically have worse trajectories than the people who stay. Removing them makes any drug look better, and it makes the drug with better persistence look better still.
Persistence can differ sharply between GLP-1 drugs and formulations. A UK cohort measured it and found discontinuation ran from 36.9% to 55.8% depending on the drug, though tirzepatide was not among them. A comparison that censors on discontinuation is partly measuring that.
Which to believe
The trial-emulation study has the stronger methodology. Before extending to a broader population, it first reproduced the reference randomized trials, checking that its methods recovered the known answers on every individual endpoint except all-cause mortality in one trial. Only then did it apply those methods to new questions.[1]
That is calibration, and it is rare. Most observational studies ask you to trust their design; this one demonstrated it against a known answer first. Its conclusion, comparable cardiovascular benefit between the two drugs in clinical practice, is the one we would weight more heavily.
Frequently Asked Questions
References
- 1.Krüger N, Schneeweiss S, Desai RJ, et al. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice Nature Medicine. 2026. PMID: 41207920.
- 2.Wilson L, Zhao Z, Divino V, et al. Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world Diabetes, Obesity and Metabolism. 2026. PMID: 41491349.
Compare the sellers
Related research
GLP-1 Drugs and Blood Pressure: How Much It Falls, and What Happens When You Stop
On the FDA labels, systolic blood pressure fell about 4 to 7 points more than placebo on tirzepatide and 3 to 5 on semaglutide. 24-hour monitoring confirmed it, weight loss explained most of it, and in the withdrawal trials much of it came back.
8 min read
Semaglutide and Peripheral Artery Disease: The Label, the Options and Coverage
STRIDE showed semaglutide 1 mg improved walking distance in type 2 diabetes with PAD, and Novo Nordisk filed for a US label change in 2025. Ozempic's label still lists no PAD use, but PAD already counts as cardiovascular disease on the Ozempic and Wegovy labels.
7 min read
GLP-1s and Atrial Fibrillation: Reading a 42% Headline
A meta-analysis of ten trials in 12,651 patients found a 42% lower risk of new atrial fibrillation on semaglutide. None of those trials was designed to measure it, and the absolute numbers were never published.
6 min read
Semaglutide and Days Spent in Hospital
A prespecified analysis of SELECT found hospital days falling from 176.2 to 157.2 per 100 patient-years. It is a modest number from a randomized trial, which is what makes it trustworthy.
5 min read
Mounjaro Heart Protection: What SURPASS-CVOT Found and What FDA Approved
In August 2026 FDA gave Mounjaro a heart-risk indication for high-risk adults with type 2 diabetes. SURPASS-CVOT found 12.2% vs 13.1% major heart events against Trulicity: non-inferior, not superior. Zepbound has no heart indication; SURMOUNT-MMO is due in 2027.
7 min read
How Far You Can Walk
Peripheral artery disease stops people walking, and almost nothing improves it. A trial of 792 people measured actual walking distance, and the spread matters as much as the median.
6 min read
Where to get tirzepatide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Bodybuilding Health+
Seeing what it charges before you answer any medical questions
From $209/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $129/mo
Get started →Found
People who want clinician visits billed to commercial insurance, with compounded medication in the plan price
From $359/mo
Get started →